We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.

St. Gallen International Breast Cancer Conference Expert Panel


St. Gallen Expert Panel Highlights Importance of Genomic Testing for Patients with Early Stage Breast Cancer

St. GallenThe use of genomic tests to help tailor treatment for patients with breast cancer was recently endorsed by the St. Gallen International Breast Cancer Conference Expert Panel. In a review of its guidelines for early-stage breast cancer, the panel recognized the value of the Oncotype DX Breast Recurrence Score® test in helping guide treatment decisions on adjuvant chemotherapy in node-positive and node-negative disease

As the only test supported by a majority of panelists, Oncotype DX was endorsed for both its predictive and prognostic abilities – identifying patients who will benefit from chemotherapy and likelihood of breast cancer recurrence.

"We are pleased that this expert panel once again recognized the value of the Oncotype DX test. An extensive body of clinical evidence highlights the unique ability of our test to identify both patients who can be spared chemotherapy and - importantly - those who will clearly benefit from it, while providing a positive impact on healthcare systems," said Calvin Chao, vice president of global medical affairs at Genomic Health.

The updated St. Gallen guidelines have been recently published online in the Advance Access section of Annals of Oncology and will appear in a future print issue. The Oncotype DX Breast Recurrence Score test was also recently included in the latest edition of the American Joint Committee on Cancer (AJCC) criteria for breast cancer staging, which, for the first time, added molecular markers to its staging criteria.


Learn more

Oncotype DX My Colon Cancer Coach